Clinical trials
Metastatic Colorectal Cancer clinical trials
Below are recruiting metastatic colorectal cancer clinical trials, each written for real people, not researchers. We’re tracking 546 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07050394RecruitingEarly Phase 1
Experimental drug for advanced colorectal cancer
This trial tests a new experimental drug (HNF4α srRNA) given through a vein for people with advanced colorectal cancer that has not responded to or cannot be treated with standard therapies. The goal is to see if this treatment can help shrink or slow the growth of the cancer.
Shanghai, None SelectedAges 18 years+ - NCT07035886Recruiting
Fruzaqla for metastatic colorectal cancer in South Korea
This study monitors the safety and effectiveness of Fruzaqla (a targeted therapy taken as a pill) in adults with advanced colorectal cancer that has spread to other parts of the body. It is being done in South Korea to gather real-world information about how well the treatment works and how patients respond.
SeoulAges 18 years+ - NCT06992648RecruitingPhase 3
Two drug combos for advanced colorectal cancer
This trial tests a two-drug combination (trifluridine/tipiracil plus regorafenib) against a standard pair (trifluridine/tipiracil plus bevacizumab) for people with advanced colorectal cancer that has stopped responding to prior treatments. It aims to find which combination works better.
Hangzhou, ZhejiangAges 18 years+ - NCT05908643RecruitingPhase 1/Phase 2
First test of pTTL for advanced colorectal cancer
This trial tests pTTL, a personalized cancer treatment made from your tumor and immune cells, in people with advanced (stage IV) colorectal cancer. It’s designed to see whether pTTL is safe and potentially effective when standard treatments have been used or can’t be used.
Stockholm, Stockholm CountyAges 18 years+ - NCT07042685RecruitingPhase 2
5-FU and Fruquintinib for advanced colorectal cancer
This trial tests a combination of two drugs (5-FU and fruquintinib) in people with advanced colorectal cancer that cannot be removed by surgery or has spread. It is for those who have not had chemotherapy before.
Houston, TexasAges 18 years+ - NCT07043387Recruiting
Simplified radioembolization for liver cancer and bile duct cancer
This trial tests a streamlined way to deliver radioactive beads (radioembolization) directly to liver tumors in people with metastatic liver cancer or bile duct cancer. It aims to make treatment simpler and safer while still effectively targeting tumors.
Goyang-siAges 19 years+ - NCT07018869RecruitingPhase 3
A website to improve follow-up care for colorectal cancer survivors
This study tests if an educational website, viewed with a supporter, can improve follow-up care for people who had surgery for stage II or III colorectal cancer. It aims to help patients and their supporters find helpful information together.
Anchorage, AlaskaAges 18 years+ - NCT07011576RecruitingPhase 2
Fruquintinib plus FOLFIRI for second-line metastatic colorectal cancer
This trial tests a combination of two drugs, fruquintinib and FOLFIRI chemotherapy, as a second treatment option for people with metastatic colorectal cancer. It is designed for patients who have already received one prior treatment containing oxaliplatin, fluoropyrimidine, and bevacizumab.
Denver, ColoradoAges 18 years+ - NCT06992258RecruitingPhase 2
Comparing two drug combinations for advanced colorectal cancer
This trial tests whether adding TAS-102 to fruquintinib works better than fruquintinib alone for people with advanced colorectal cancer that has stopped responding to other treatments.
New Haven, ConnecticutAges 18 years+ - NCT06974110RecruitingPhase 1
Study of a new drug for advanced solid tumors with MSI-H or dMMR
This trial tests an oral medication called MOMA-341 in people with advanced solid tumors that have high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). It aims to see if the drug can help when prior immunotherapy hasn't worked or isn't available.
Phoenix, ArizonaAges 18 years+ - NCT06959589Enrolling by invitationPhase 2
Combination therapy for KRAS G12C mutated colorectal cancer
This trial tests a new drug combination (IBI351, cetuximab, and FOLFIRI) as first treatment or as a second treatment after standard chemotherapy for people with KRAS G12C mutated colorectal cancer that has spread. The goal is to see if it works well and is safe.
Hangzhou, ZhejiangAges 18–75 - NCT06959550RecruitingPhase 2
Ivonescimab for previously treated metastatic colorectal cancer
This trial tests a new drug called ivonescimab, which is a bispecific antibody that targets both PD-1 and VEGF. It is for people with metastatic colorectal cancer who have already tried standard treatments and may or may not have received immunotherapy before, depending on their tumor type.
Houston, TexasAges 18 years+ - NCT06958419RecruitingPhase 2/Phase 3
Short radiation plus targeted drugs for advanced colon cancer
This trial tests a combination of short-course radiation, chemotherapy, targeted therapy (bevacizumab), and an immunotherapy drug (PD-1 inhibitor) for people with advanced colorectal cancer that has spread and is not curable with surgery. It aims to see if this approach can help shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT05771181RecruitingPhase 2
Test vitamin E plus two cancer drugs for metastatic colon cancer
This trial tests whether adding vitamin E to two cancer medicines (fruityquintinib and tislelizumab) can work better in people with metastatic colorectal cancer that is mismatch-repair stable (MSS). It may help if your cancer has grown despite standard treatment, and you can meet the study’s safety and blood/organ requirements.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06948448RecruitingPhase 2
New treatment for advanced colorectal cancer with PD-L1 biomarker
This trial tests a new drug (ONO-4578) combined with standard chemotherapy and immunotherapy for people with advanced colorectal cancer that has not been treated before and has a specific marker called PD-L1. The goal is to see if this combination works better than the usual treatment.
Phoenix, ArizonaAges 18 years+ - NCT06951503RecruitingPhase 3
AK112 plus chemo for first-line metastatic colorectal cancer
This trial tests a new drug called AK112 combined with chemotherapy as a first treatment for people with metastatic colorectal cancer. The goal is to see if the combination helps shrink tumors and improve survival better than chemotherapy alone.
Guanzhou, GuangdongAges 18–75 - NCT06934538RecruitingPhase 1/Phase 2
Immunotherapy trial for advanced colorectal cancer
This trial tests a new immunotherapy drug (STC-1010) for people with colorectal cancer that cannot be removed by surgery or has spread. It aims to see if the drug can shrink tumors or slow the disease.
Baltimore, MarylandAges 18–75 - NCT06936527Enrolling by invitationPhase 1/Phase 2
XS-03 plus chemotherapy and bevacizumab for metastatic colorectal cancer with RAS mutation
This trial tests an experimental drug called XS-03 combined with standard chemotherapy (FOLFOX or FOLFIRI) plus a targeted therapy (bevacizumab) for people with metastatic colorectal cancer that has a RAS mutation. The goal is to see if adding XS-03 helps shrink tumors or slows cancer growth better than current treatments.
BeijingAges 18–75 - NCT06937567RecruitingEarly Phase 1
CDH17 car-t therapy for advanced solid tumors
This trial tests a new treatment called CDH17 CAR-T for people with advanced solid tumors like colorectal, stomach, pancreatic, or bile duct cancer. It is for patients who have tried other treatments without success. The therapy uses your own immune cells, modified to target a protein called CDH17 found on some cancer cells.
Hangzhou, ZhejiangAges 18–70 - NCT06938971Recruiting
Exercise for quality of life in metastatic colorectal cancer
This trial tests whether a combination of resistance and aerobic exercise can improve quality of life for people starting their first round of chemotherapy for metastatic colorectal cancer. If you are newly diagnosed and not already exercising regularly, this study may help you feel better during treatment.
CopenhagenAges 18 years+ - NCT06936488Enrolling by invitation
Study of Ivonescimab with TAS-102 for advanced colorectal cancer
This trial tests a combination of two drugs – ivonescimab (a type of immunotherapy) and TAS-102 (a chemotherapy) – for people with advanced colorectal cancer that has not responded to at least two prior chemotherapies. The goal is to see if this new combo can shrink tumors or slow cancer growth.
Huai'an, JiangsuAges 18–75 - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Los Angeles, CaliforniaAges 18 years+ - NCT06911970Recruiting
Exercise and immune response in cancer treatment
This trial tests whether aerobic exercise can help your immune system fight cancer better during chemotherapy or immunotherapy. It is for people with breast or colon cancer that has not spread to other parts of the body.
Sherbrooke, QuebecAges 40–70 - NCT06907342RecruitingPhase 2
Personalized chemo selection for advanced colorectal cancer
This trial tests whether a functional test on a tumor biopsy can help choose the best first chemotherapy regimen (FOLFOX or FOLFIRI) for people with metastatic colorectal cancer. It aims to improve outcomes by matching treatment to each person's unique tumor biology.
TrondheimAges 18 years+
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic colorectal cancer?
- Yes. Clin2 currently lists 546 recruiting metastatic colorectal cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic colorectal cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic colorectal cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Colorectal Cancer (CRC)
- Metastatic Colorectal Cancer (mCRC)
- Unresectable Metastatic Colorectal Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Refractory Metastatic Colorectal Cancer
- MSS Metastatic Colorectal Cancer
- Microsatellite Stable Metastatic Colorectal Cancer
- Non-metastatic Colorectal Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.